Skip to main content
SpringerLink
Log in

Glucagon-like Peptide-1 Receptor Agonists

  • Chapter
  • First Online:
Stroke Revisited: Diabetes in Stroke

Part of the book series: Stroke Revisited ((STROREV))

  • 511 Accesses

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients. GLP-1 presents a glucose-lowering effect via their insulinotropic action on pancreatic β-cells. In addition to their insulinotropic effect, GLP-1 also has pleiotropic actions associated with clinical benefits. GLP-1RAs are a well-established effective treatment for patients with T2DM. GLP-1RAs have antihyperglycemic effects with a low risk of hypoglycemia and reduce body weight. Additionally, GLP-1RAs have beneficial effects on cardiovascular risk factors, such as blood pressure and lipid levels. Large randomized cardiovascular outcome trials and meta-analyses demonstrated that GLP-1RAs reduce cardiovascular disease in T2DM patients. GLP-1RAs are recommended as part of glucose-lowering regimens in patients with T2DM and established cardiovascular disease, or those at high risk. Renal protective and beneficial effects of GLP-1RAs on nonalcoholic fatty liver disease have also been suggested.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46–52.

    Article  CAS  PubMed  Google Scholar 

  2. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741–4.

    Article  CAS  PubMed  Google Scholar 

  3. Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014;124(10):4223–6.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Secher A, Jelsing J, Baquero AF, Hecksher-Sorensen J, Cowley MA, Dalboge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819–37.

    Article  CAS  PubMed  Google Scholar 

  6. Dai C, Hang Y, Shostak A, Poffenberger G, Hart N, Prasad N, et al. Age-dependent human beta cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling. J Clin Invest. 2017;127(10):3835–44.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000;141(12):4600–5.

    Article  CAS  PubMed  Google Scholar 

  8. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology. 2002;143(8):3152–61.

    Article  CAS  PubMed  Google Scholar 

  9. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(11):1788–803.

    Article  CAS  PubMed  Google Scholar 

  10. Nauck MA, Meier JJ, Cavender MA. Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like Peptide-1 receptor agonists and dipeptidyl Peptidase-4 inhibitors. Circulation. 2017;136(9):849–70.

    Article  CAS  PubMed  Google Scholar 

  11. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.

    Article  CAS  PubMed  Google Scholar 

  13. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly Exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.

    Article  CAS  PubMed  Google Scholar 

  14. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.

    Article  CAS  PubMed  Google Scholar 

  15. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.

    Article  CAS  PubMed  Google Scholar 

  16. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–51.

    Article  CAS  PubMed  Google Scholar 

  17. Pujadas G, Drucker DJ. Vascular biology of glucagon receptor superfamily peptides: mechanistic and clinical relevance. Endocr Rev. 2016;37(6):554–83.

    Article  CAS  PubMed  Google Scholar 

  18. Lorenz M, Lawson F, Owens D, Raccah D, Roy-Duval C, Lehmann A, et al. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017;16(1):6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Wei R, Ma S, Wang C, Ke J, Yang J, Li W, et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner. Am J Physiol Endocrinol Metab. 2016;310(11):E947–57.

    Article  PubMed  Google Scholar 

  20. Dai Y, Mehta JL, Chen M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther. 2013;27(5):371–80.

    Article  CAS  PubMed  Google Scholar 

  21. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59(4):1030–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004;89(6):3055–61.

    Article  CAS  PubMed  Google Scholar 

  23. Yin W, Xu S, Wang Z, Liu H, Peng L, Fang Q, et al. Recombinant human GLP-1(rhGLP-1) alleviating renal tubulointestitial injury in diabetic STZ-induced rats. Biochem Biophys Res Commun. 2018;495(1):793–800.

    Article  CAS  PubMed  Google Scholar 

  24. Lyseng-Williamson KA. Glucagon-like Peptide-1 receptor analogues in type 2 diabetes: their use and differential features. Clin Drug Investig. 2019;39(8):805–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Waldrop G, Zhong J, Peters M, Goud A, Chen YH, Davis SN, et al. Incretin-based therapy in type 2 diabetes: an evidence based systematic review and meta-analysis. J Diabetes Complicat. 2018;32(1):113–22.

    Article  Google Scholar 

  26. Levin PA, Nguyen H, Wittbrodt ET, Kim SC. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, Metab Syndr Obes: Targets and Therapy. 2017;10:123–39.

    Article  CAS  Google Scholar 

  27. Singh S, Wright EE Jr, Kwan AY, Thompson JC, Syed IA, Korol EE, et al. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2017;19(2):228–38.

    Article  CAS  PubMed  Google Scholar 

  28. Tran S, Retnakaran R, Zinman B, Kramer CK. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2018;20(Suppl 1):68–76.

    Article  CAS  PubMed  Google Scholar 

  29. Sfairopoulos D, Liatis S, Tigas S, Liberopoulos E. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones (Athens). 2018;17(3):333–50.

    Article  Google Scholar 

  30. Sun F, Chai S, Li L, Yu K, Yang Z, Wu S, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J Diabetes Res. 2015;2015:157201.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, et al. Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis. Endocrine. 2015;48(3):794–803.

    Article  CAS  PubMed  Google Scholar 

  32. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.

    Article  CAS  PubMed  Google Scholar 

  33. Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–85.

    Article  CAS  PubMed  Google Scholar 

  34. Willard FS, Sloop KW. Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor. Exp Diabetes Res. 2012;2012:470851.

    PubMed  PubMed Central  Google Scholar 

  35. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like Peptide-1. Cell Metab. 2018;27(4):740–56.

    Article  CAS  PubMed  Google Scholar 

  36. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–42.

    Article  CAS  PubMed  Google Scholar 

  37. Mudaliar S, Henry RR. Incretin therapies: effects beyond glycemic control. Am J Med. 2009;122(6 Suppl):S25–36.

    Article  PubMed  Google Scholar 

  38. Bellastella G, Maiorino MI, Longo M, Scappaticcio L, Chiodini P, Esposito K, et al. Glucagon-like Peptide-1 receptor agonists and prevention of stroke systematic review of cardiovascular outcome trials with Meta-analysis. Stroke. 2020;51(2):666–9.

    Article  PubMed  Google Scholar 

  39. American DA. 9. Pharmacologic approaches to glycemic treatment: standards of medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98–S110.

    Article  Google Scholar 

  40. Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):859–69.

    Article  CAS  PubMed  Google Scholar 

  41. Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–48.

    Article  CAS  PubMed  Google Scholar 

  42. Bethel MA, Mentz RJ, Merrill P, Buse JB, Chan JC, Goodman SG, et al. Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly Exenatide: insights from the EXSCEL trial. Diabetes Care. 2020;43(2):446–52.

    Article  PubMed  Google Scholar 

  43. Yin WL, Bain SC, Min T. The effect of glucagon-like Peptide-1 receptor agonists on renal outcomes in type 2 diabetes. Diabetes Ther. 2020;11(4):835–44.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Sofogianni A, Filippidis A, Chrysavgis L, Tziomalos K, Cholongitas E. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: an update. World J Hepatol. 2020;12(8):493–505.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, et al. Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis. Int J Mol Sci. 2020;21(6):1907. https://doi.org/10.3390/ijms21061907.

    Article  CAS  PubMed Central  Google Scholar 

  46. Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M, et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2015;45(3):269–78.

    Article  CAS  PubMed  Google Scholar 

  47. Fan H, Pan Q, Xu Y, Yang X. Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq Bras Endocrinol Metabol. 2013;57(9):702–8.

    Article  PubMed  Google Scholar 

  48. Kalogirou M, Sinakos E. Treating nonalcoholic steatohepatitis with antidiabetic drugs: will GLP-1 agonists end the struggle? World J Hepatol. 2018;10(11):790–4.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Bettge K, Kahle M. Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336–47.

    Article  CAS  PubMed  Google Scholar 

  50. Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3–4):202–30.

    Article  PubMed  Google Scholar 

  51. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide--the FDA’s review of a new antidiabetic therapy. N Engl J Med. 2010;362(9):774–7.

    Article  CAS  PubMed  Google Scholar 

  52. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes. 2012;61(5):1250–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473–86.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Republic of Korea

    Ja Young Jeon & Hae Jin Kim

Authors
  1. Ja Young Jeon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hae Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hae Jin Kim .

Editor information

Editors and Affiliations

  1. Department of Neurology, Seoul National University Hospital, Seoul, Korea (Republic of)

    Seung-Hoon Lee

  2. Korean Cerebrovascular Research Institute, Seoul, Korea (Republic of)

    Dong-Wan Kang

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jeon, J.Y., Kim, H.J. (2021). Glucagon-like Peptide-1 Receptor Agonists. In: Lee, SH., Kang, DW. (eds) Stroke Revisited: Diabetes in Stroke. Stroke Revisited. Springer, Singapore. https://doi.org/10.1007/978-981-16-5123-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-5123-6_14

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-5122-9

  • Online ISBN: 978-981-16-5123-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation